OMEROS CORP Debt Securities, Available-for-sale, Amortized Cost, Current
OMEROS CORP (OMER) had Debt Securities, Available-for-sale, Amortized Cost, Current of $121.64 million as of 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Notes
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2024-11-13
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $121.64M.
- 2024-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $156.79M.
- 2024-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $228.50M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $164.74M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2024-09-30 | $121.64M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $156.79M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $228.50M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $164.74M 10-Q · filed 2024-11-13 |
| 2023-09-30 | $279.67M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $334.68M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $367.53M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $183.91M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |